| Literature DB >> 35573991 |
Jinzhi Zhang1, Jiao Nie1, Min Zou2, Qishan Zeng2, Yue Feng1, Zhenyi Luo1, Huatian Gan1,2.
Abstract
Background: Sexual dysfunction (SD) in patients who suffer from inflammatory bowel disease (IBD) has not attracted widespread attention, and thus research studies are scarce. Objective: This study aims to evaluate the rates of SD in IBD compared with healthy individuals and elucidate the associated factors.Entities:
Keywords: Crohn’s disease; erectile dysfunction; inflammatory bowel disease; sexual dysfunction; ulcerative colitis
Mesh:
Year: 2022 PMID: 35573991 PMCID: PMC9094619 DOI: 10.3389/fendo.2022.881485
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Participants characteristics.
| Female patients | Female controls |
| Male patients | Male controls |
| |
|---|---|---|---|---|---|---|
|
|
|
|
| |||
| Age, years | .694 | .971 | ||||
| < 41 | 59 (70.2) | 54 (69.2) | 85 (68.5) | 75 (67.0) | ||
| 41-59 | 23 (27.4) | 20 (25.6) | 35 (28.2) | 33 (29.5) | ||
| > 59 | 2 (2.4) | 4 (5.1) | 4 (3.2) | 4 (3.6) | ||
| Body mass index, kg/m2 | .007** | .000** | ||||
| < 18.5 | 33 (39.3) | 16 (20.5) | 26 (21.0) | 2 (1.8) | ||
| 18.5 – 25 | 47 (56.0) | 55 (70.5) | 89 (71.8) | 66 (58.9) | ||
| 25 – 30 | 2 (2.4) | 7 (9.0) | 9 (8.3) | 35 (31.3) | ||
| > 30 | 2 (2.4) | 0 | 0 | 9 (8.0) | ||
| Education, | .976 | .836 | ||||
| Basic level | 7 (8.3) | 6 (7.1) | 9 (7.3) | 6 (5.4) | ||
| Medium level | 32 (38.1) | 29 (37.2) | 36 (29.0) | 33 (29.5) | ||
| High level | 45 (53.6) | 43 (55.1) | 79 (63.7) | 73 (65.2) | ||
| Relationship status, | .248 | .161 | ||||
| In a relationship | 25 (29.8) | 17 (21.8) | 34 (27.4) | 22 (19.6) | ||
| Married | 59 (70.2) | 61 (78.2) | 90 (72.6) | 90 (80.4) | ||
| Active smoker, | 2 (2.4) | 2 (2.6) | 1.000 | 41 (33.1) | 50 (44.6) | .068 |
| Active Drinking, | 6 (7.1) | 6 (7.7) | .894 | 26 (21.0) | 31 (27.7) | .229 |
| Profession, | .406 | .263 | ||||
| Workers | 8 (9.5) | 7 (9.0) | 13 (10.5) | 17 (15.2) | ||
| Farmers and herdsmen | 11 (13.1) | 8 (10.3) | 20 (16.1) | 11 (9.8) | ||
| Staff | 20 (23.8) | 28 (35.9) | 49 (39.5) | 52 (46.4) | ||
| Self-employed | 45 (53.6) | 35 (43.8) | 42 (33.9) | 32 (28.6) | ||
| Address, | .168 | .054 | ||||
| City | 46 (54.8) | 51 (65.4) | 69 (55.6) | 76 (67.9) | ||
| Countryside | 38 (45.2) | 27 (34.6) | 55 (44.4) | 36 (32.1) | ||
| Anxiety, | 34 (40.5) | 18 (23.1) | .005** | 52 (41.9) | 26 (23.2) | .003** |
| Depression, | 21 (25.0) | 4 (5.1) | .002** | 21 (16.9) | 3 (2.7) | .001** |
| Self-reported sexual dysfunction, | 8 (9.5) | 0 | .007** | 3 (2.4) | 12 (9.7) | .017* |
*p < 0.05, **p < 0.01.
Characteristics of the IBD population.
| Female patients | Male patients | |
|---|---|---|
| CD, | 54 (64.3) | 79 (63.7) |
| UC, | 30 (35.7) | 45 (36.3) |
| Median CDAI (IQR) | 180 (87.3-280.8) | 150 (75.5-185.5) |
| Median Mayo score (IQR) | 5 (3-10.5) | 7.5 (4-10.3) |
| Active disease, | ||
| Mild disease course | 13 (15.5) | 34 (27.4) |
| Moderate disease course | 23 (27.4) | 26 (21.0) |
| Severe disease course | 8 (9.5) | 9 (7.3) |
| Median disease duration (IQR), years | 5 (2-8) | 4 (2-7) |
| Active perianal disease, | 21 (25.0) | 14 (11.3) |
| Previous surgery, | 30 (35.7) | 46 (37.1) |
| Presence of a stoma, n (%) | 4 (4.8) | 3 (2.4) |
| 5-ASA, current use, n (%) | 40 (47.6) | 60 (48.4) |
| Immunosuppressant, current use, n (%) | 11 (13.1) | 10 (8.1) |
| Biological therapy, current use, n (%) | 45 (53.6) | 66 (53.2) |
| Corticosteroids, current use, n (%) | 8 (9.5) | 10 (8.1) |
| Psychotropic medication, current use, | 2 (2.4) | 8 (6.5) |
CD, Crohn’s disease; CDAI, Crohn’s disease activity index; UC, ulcerative colitis; IBD, inflammatory bowel disease; IQR, interquartile range; 5-ASA, 5-Aminosalicylic acid.
Defined as CDAI score is 150-220 or Mayo score is 3-5.
Defined as CDAI score is 220-450 or Mayo score is 6-10.
Defined as CDAI score > 450 or Mayo score is 11-12.
Figure 1Sexual function of IBD female patients compared with healthy controls according to FSFI.
Prevalence and subgroup analysis of sexual dysfunction in IBD patients.
| Women, | Men, | |
|---|---|---|
| IBD | 52 (61.9)** | 54 (43.5)** |
| CD | 33 (61.1)** | 35 (44.3)** |
| UC | 19 (63.3)** | 19 (42.4)** |
| Disease Staging | ||
| In remission | 19 (47.5)** | 17 (30.9)** |
| In active disease | 32 (75.0)**,ξ | 36 (53.6)**,ξ |
| Active disease index | ||
| Mildly active disease | 8 (61.5)** | 16 (47.1)** |
| Moderately active disease | 17 (73.9)**,ξ | 15 (57.7)**,ξξ |
| Severely active disease | 7 (87.5)**,ξ | 5 (66.7)**,ξξ |
| Healthy controls | 20 (24.4) | 14 (12.5) |
*P < 0.05, **P < 0.01, vs. healthy controls; ξ P < 0.05, ξξ P < 0.01, vs. in remission.
CD, Crohn’s disease; IBD, inflammatory bowel disease; UC, ulcerative colitis.
Age-matched comparison of IBD patients and healthy controls for FSFI or IIEF-5.
| IBD patients Mean ( | Healthy controls Mean ( |
| |
|---|---|---|---|
| FSFI | |||
| Desire | 3.0 (79) | 4.0 (78) | .000** |
| Arousal | 3.6 (79) | 4.5 (78) | .000** |
| Lubrication | 4.4 (79) | 4.9 (78) | .000** |
| Orgasm | 4.1 (79) | 4.8 (78) | .000** |
| Global satisfaction | 4.2 (79) | 4.5 (78) | .019* |
| Pain | 4.6 (79) | 4.6 (78) | .612 |
| Total score | 23.8 (79) | 27.2 (78) | .000** |
| IIEF-5 | |||
| Total score | 20.4 (119) | 22.2 (112) | .002** |
Mean score, number of matched individuals, paired t-test p-value. *P <.05, **P <.01.
FSFI, female sexual function index; IBD, inflammatory bowel disease; IIEF-5, a simplified version of the international index of erectile function.
Figure 2Erectile function of IBD male patients compared with healthy controls according to IIEF-5.
Comparison of IBD patients and healthy controls for IIEF-5.
| IBD Patients, | Healthy controls, |
| |
|---|---|---|---|
| Non-ED | 70 (56.5) | 98 (87.5) | |
| Mild ED | 34 (27.4) | 10 (8.9) | <0.01** |
| Mild-moderate ED | 14 (11.3) | 3 (2.7) | 0.001** |
| Moderate ED | 6 (4.8) | 1 (0.9) | 0.044* |
| Severe ED | – | – | |
| Erectile dysfunction | 54 (43.5) | 14 (12.5) | <0.01** |
Number of individuals, Chi-squared p-value. *p < 0.05, **P < 0.01.
IBD, inflammatory bowel disease; IIEF-5, a simplified version of the international index of erectile function; ED, erectile dysfunction.
Defined as IIEF-5 score is 17-21.
Defined as IIEF-5 score is 12-16.
Defined as IIEF-5 score is 8-11.
Defined as IIEF-5 score is 5-7.